How Psychedelics Work, in Under Six Minutes

In this Big Think talk, psychedelic researcher Dr. Matthew Johnson of Johns Hopkins lays out, in under six minutes, how psychedelics are thought to work: from a single serotonin receptor to changes in how brain regions communicate. He frames the question as a bridge between biology and psychology, arguing neither side alone explains why these substances can shift a person's sense of reality, and for some, their sense of self. The talk is a primer on mechanism, not a case for use.

A word that means more than it used to

Johnson starts with the term itself. "Psychedelic" comes from roots meaning mind manifesting, an idea he ties to these compounds acting as non-specific amplifiers: the same substance can produce a euphoric experience in one context and a difficult one in another. He distinguishes the classic psychedelics, psilocybin, LSD, DMT (the active compound in ayahuasca), and mescaline (found in peyote), which share a primary mechanism at one serotonin receptor, from substances some researchers also call psychedelic on looser grounds: MDMA, which works mainly by releasing serotonin, and ketamine, which acts primarily on the glutamate system. Scientists disagree on the category's edges. Johnson's working definition: drugs capable of profoundly altering a person's sense of reality, including their sense of self.

From receptor to network

Johnson walks through the cascade using psilocybin as an example. After ingestion, psilocybin converts to psilocin, the compound that reaches the brain and binds the serotonin 2A receptor, much as the brain's own serotonin does. That binding cascades outward, affecting the glutamate system, and at a broader level Johnson describes a marked increase in communication across brain regions that normally operate somewhat separately, what he calls different "silos." This cross-talk is one candidate explanation for why people sometimes report viewing themselves from a radically different vantage point during a session, a shift often discussed in relation to the default mode network, the network associated with the brain's sense of a fixed, narrating self.

Why the experience itself seems to matter

Johnson notes the mechanism is not just receptor chemistry. Based on animal research, he points to signs of increased neuroplasticity in the days following a session, a window in which the brain may be more primed to learn and settle into a new baseline. But the psychological content of the session, not only the pharmacology, seems important to how lasting any change turns out to be. That is part of why he sees psilocybin treatment as closer to psychotherapy than to a conventional medication taken and set aside.

Why now: the psychedelic renaissance

Johnson closes by situating the research wave, sometimes called a renaissance, within a broader mental health landscape: a persistent mental health crisis, reduced pharmaceutical investment, and the limits of options such as addiction substitution therapies, which he says are useful but often do not reach the roots of the disorder. He is explicit that psychedelics are not a cure-all, while still describing the field's promise as substantial.

Key takeaways

• ●Johnson frames psychedelics at the intersection of biology (receptor effects) and psychology (the meaning of the experience).
• ●"Psychedelic" is contested: classic psychedelics (psilocybin, LSD, DMT, mescaline) share a serotonin 2A mechanism; MDMA and ketamine work through different systems.
• ●Psilocybin converts to psilocin, which binds the serotonin 2A receptor and appears to trigger a cascade affecting glutamate and cross-brain communication.
• ●That cross-network activity relates to the default mode network, linked to the brain's sense of a fixed self.
• ●Animal research suggests heightened neuroplasticity may follow a session, which may support learning and lasting change.
• ●The session's psychological content, not receptor binding alone, seems central to outcomes, which is why Johnson likens the model to psychotherapy.
• ●He links the research surge to a mental health crisis, pharmaceutical stagnation, and the limits of addiction treatments, while cautioning psychedelics are not a cure for everyone.

"What psychedelic means from its linguistic roots is mind manifesting." (Dr. Matthew Johnson, Big Think)

"Nothing is going to be a miracle cure for everyone, nonetheless they have so much promise." (Dr. Matthew Johnson, Big Think)

For substance-specific detail, see the Psylopedia profiles on psilocybe cubensis and MDMA, or the article on how psychedelics change the brain.